NIH STTR Fast-Track grant helps propel Sensydia’s non-invasive CPS platform building on recent funding round
Non-invasive cardiac diagnostic company Sensydia announced today that it was awarded a Fast-Track Small Business grant from the National Heart, Lung, and Blood Institute (NHLBI), part of the National Institutes of Health (NIH).
The award provides Sensydia with non-dilutive funding for the development and clinical testing of the machine learning algorithms for the Cardiac Performance System (CPS), designed to enable earlier detection and therapy guidance for patients with heart failure and pulmonary hypertension.
“We are honored to be a recipient of this competitive award from the NIH/NHLBI and look forward to unlocking the capabilities of AI-based cardiac assessment to provide personalized care to patients suffering from heart disease,” said Aman Mahajan, MD, Sensydia Chief Medical Officer.
Phase I of the grant proposal is budgeted for approximately $600,000 and Phase II for $2.4M, following successful completion of Phase I milestones.
This NIH award marks a significant milestone for Sensydia, a company committed to developing AI-based solutions for the diagnosis and management of cardiopulmonary diseases. Sensydia recently raised $8M in venture funding.
The Small Business Technology Transfer (STTR) program of the NIH supports U.S.-owned small businesses with early-stage capital for creating innovative technologies to improve human health. The STTR Fast-Track streamlines funding for Phases I and II, with feasibility established in Phase I and technology development in Phase II.
Visit AITechPark for cutting-edge Tech Trends around AI, ML, Cybersecurity, along with AITech News, and timely updates from industry professionals!
